Novartis has announced it would not raise drug prices in the US this year, while Merck & Co announced huge cuts in the price of its hepatitis drug following pressure from president Trum
Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to a skin drug, which will further strengthen Novartis’s leadership position in the immunolo
The pharmaceutical industry celebrated the 70th anniversary of the NHS by recognising the myriad contributions that the sector has made to the lives of many people.
Revolutionary CAR-T cell therapies for blood cancer could be on the European market within a few months after they were given the green light by regulators – but they face further price scr
Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the biotech to the leading pack of the migraine cure race, among Allergan, Amgen a